{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-010525","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.753941+00:00","generated_at":"2026-05-27T03:11:12.766745+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones","bullets":["Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.","Milestone payments up to $22M, including $1.5M for candidate nomination and $2.5M for first Phase 1 dosing.","Low single-digit royalty on antibody products; royalty term up to 12 years after first sale.","Paragon agrees not to conduct new anti-IL-17A/F campaigns in the field for at least 5 years.","Company may terminate agreement on 60 days' notice; termination for breach or insolvency."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-010525","json":"https://secwatch.observer/filing/0001213900-25-010525.json","markdown":"https://secwatch.observer/filing/0001213900-25-010525.md","text":"https://secwatch.observer/filing/0001213900-25-010525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/0001213900-25-010525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/ea0229970-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:11:12.766745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}